ArticleTranslational lung cancer research2026
Heterogeneous efficacy and predictors of response to immunotherapy in driver-mutant advanced NSCLC: a focus on EGFR and KRAS subtypes.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors improve survival in driver-negative advanced non-small cell lung cancer (NSCLC); however, their efficacy in oncogene-driven NSCLC has not yet been established. This study evaluated the clinical and molecular predictors of immunotherapy outcomes in this population. Methods: We conducted a retrospective, two-center cohort study of 129 patients with advanced NSCLC harboring driver mutations who received PD-1/PD-L1 inhibitors (either as monotherapy or in combination with other antineoplastic drugs). Treatment efficacy and predictors were analyzed in the overall cohort and key mutational subgroups, including epidermal growth factor receptor ( Results: The efficacy of immunotherapy varied significantly by genotype. Patients with Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.